SCHEMBL428500

SCHEMBL428500

O=C1CC(c2cccc(F)c2F)C1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.43
RECQL P46063 1/20 0.43
HTR2C P28335 2/20 0.42
HTR2B P41595 2/20 0.42
HCAR2 Q8TDS4 1/20 0.42
KDM1A O60341 2/20 0.38
KDM1B Q8NB78 1/20 0.38
CHRNB2 P17787 2/20 0.37
CHRNA4 P43681 2/20 0.37
AADAT Q8N5Z0 2/20 0.37
CHRNA7 P36544 1/20 0.37
CES2 O00748 2/20 0.36
CES1 P23141 2/20 0.36
BCHE P06276 1/20 0.36
ACHE P22303 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL425265 0.83 KDM1A (0.50) TP53RECQLHTR2CHTR2BHCAR2
SCHEMBL13293459 0.83 CXCR2 (0.37) TP53HTR2CHTR2BHCAR2
SCHEMBL30665167 0.82 CHRNB2 (0.51) TP53RECQLHTR2CHTR2BKDM1A
SCHEMBL21606744 0.82 CHRNB2 (0.51) TP53RECQLHTR2CHTR2BKDM1A
SCHEMBL29487575 0.81 HTR2C (0.40) TP53HTR2CHTR2BHCAR2CHRNB2
SCHEMBL2505519 0.81 HTR2C (0.40) TP53HTR2CHTR2BHCAR2CHRNB2
SCHEMBL26834556 0.81 KDM1A (0.41) TP53RECQLKDM1AKDM1BGAA
SCHEMBL12477783 0.79 HTR2C (0.47) HTR2CHTR2BHCAR2KDM1AKDM1B
SCHEMBL21821907 0.78 HCAR2 (0.39) TP53HTR2CHTR2BHCAR2CHRNB2
SCHEMBL29581882 0.78 HCAR2 (0.39) TP53HTR2CHTR2BHCAR2CHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120065188-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER INC 2012-03-15 US disclosed
US-20120065188-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER INC 2012-03-15 US disclosed
US-20110092480-A1 Substituted Heterocyclic Derivatives and Their Pharmaceutical Use and Compositions PFIZER INC. 2011-04-21 US disclosed
US-20110092480-A1 Substituted Heterocyclic Derivatives and Their Pharmaceutical Use and Compositions PFIZER INC. 2011-04-21 US disclosed
WO-2008139288-A2 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND COMPOSITIONS AND THEIR PHARMACEUTICAL USE AS ANTIBACTERIALS PFIZER INC. (US) 2008-11-20 WO disclosed
US-20080280879-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER INC 2008-11-13 US disclosed
US-20080280879-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER INC 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065188-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS XDH, CYP2D6, F12 TP53 2396/4885RECQL 27/4885HTR2C 1935/4885
US-20080280879-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS XDH, CYP2D6, F12 TP53 2396/4885RECQL 27/4885HTR2C 1935/4885
US-20110092480-A1 Substituted Heterocyclic Derivatives and Their Pharmaceutical Use and Compositions XDH, CYP2D6, F12 TP53 2396/4885RECQL 27/4885HTR2C 1935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.